Incyte INCY Other product royalty revenues — Total revenues

Other product segments

Similar metrics at other companies

SUPNRoyalty, licensing, and other revenues — Total revenues

$29.31M+274%

IONSOther Royalties — Revenue

$3.9M-42.5%

BMRNRoyalty and other revenues — Total revenues

$6.13M-41.6%

ANIPBrand royalties and other revenues — Net Revenues

$21.54M—

HRBRoyalty, product and other revenues — Total revenues

$171.78M-3.3%

GERNRoyalties — Total revenues

$66K-60.5%

Questions, answered.

What is Incyte's other product royalty revenues — total revenues?

Incyte (INCY) reported other product royalty revenues — total revenues of $3.25M in Q1 2026.

How has Incyte's other product royalty revenues — total revenues changed year-over-year?

Incyte's other product royalty revenues — total revenues increased by 156.5% year-over-year, from $1.27M to $3.25M.

What is the long-term trend for Incyte's other product royalty revenues — total revenues?

Over 2 years (2023 to 2025), Incyte's other product royalty revenues — total revenues has grown at a 100.1% compound annual growth rate (CAGR), from $1.97M to $7.88M.

What does other product royalty revenues — total revenues mean?

This metric represents the total revenue generated from royalty payments associated with secondary or non-core pharmaceutical products. These revenues are typically derived from licensing agreements where the company receives a percentage of net sales from partners who commercialize the intellectual property. It serves as a measure of the monetization efficiency of the company's broader drug portfolio beyond its primary flagship assets.